Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

141. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Full Text available with Trip Pro

Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis Kaplan G G, Hur C, Korzenik J, Sands B E Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to determine if dose escalation of infliximab was cost-effective in comparison with adalimumab initiation after loss of response to infliximab in patients with Crohn’s disease. The authors concluded that dose escalation would yield more quality

2007 NHS Economic Evaluation Database.

142. Adalimumab - Arthritis, psoriatic

Adalimumab - Arthritis, psoriatic Common Drug Review CEDAC Meeting – October 18; 2006 Page 1 of 3 Notice of CEDAC Final Recommendation – November 29, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ADALIMUMAB RESUBMISSION (Humira ® - Abbott Laboratories Ltd.) Description: Adalimumab is a human monoclonal antibody to tumour necrosis factor (TNF). The Canadian Expert Drug Advisory Committee had previously recommended that adalimumab be listed for patients with moderate to severe (...) active rheumatoid arthritis who meet current drug plan criteria for funding of infliximab or etanercept (see Notice of CEDAC Final Recommendation on adalimumab issued on February 11, 2005). A new indication for use in psoriatic arthritis was the basis for the resubmission. Adalimumab is approved for reducing the signs and symptoms of active arthritis in adult psoriatic arthritis patients. Dosage Forms: 40 mg in 0.8 mL solution for subcutaneous injection. The recommended dose is 40 mg every two weeks

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

143. Use of adalimumab (Humira®) within NHS Wales

Use of adalimumab (Humira®) within NHS Wales Use of adalimumab (Humira®) within NHS Wales Use of adalimumab (Humira®) within NHS Wales All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Use of adalimumab (Humira®) within NHS Wales. Penarth: All Wales Therapeutics and Toxicology

2006 Health Technology Assessment (HTA) Database.

144. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid (...) arthritis in adults and an economic evaluation of their cost-effectiveness Chen Y F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A CRD summary This review concluded that adalimumab, etanercept and infliximab are effective treatments compared with placebo for patients with rheumatoid arthritis who are not well-controlled by disease-modifying antirheumatic drugs. Combination with methotrexate seems more effective in early rheumatoid arthritis. An increased risk of infection may

2006 DARE.

145. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid (...) arthritis in adults and an economic evaluation of their cost-effectiveness Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Chen Y-F, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systematic review of the effectiveness of adalimumab

2006 Health Technology Assessment (HTA) Database.

146. Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis

Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A, Colantonio L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A, Colantonio L. Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No.79. 2006 Authors' objectives The aim of this report was to assess the use of etanercept, infliximab and adalimumab

2006 Health Technology Assessment (HTA) Database.

147. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn`s disease: the CLASSIC-I trial. Full Text available with Trip Pro

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn`s disease: the CLASSIC-I trial. BACKGROUND & AIMS: Tumor necrosis factor blockade has been shown to be an effective treatment strategy in Crohn's disease (CD). Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor (TNF). A randomized, double-blind, placebo-controlled, dose-ranging trial was performed to evaluate the efficacy of adalimumab induction therapy in patients (...) with CD. METHODS: A total of 299 patients with moderate to severe CD naive to anti-TNF therapy were randomized to receive subcutaneous injections at weeks 0 and 2 with adalimumab 40 mg/20 mg, 80 mg/40 mg, or 160 mg/80 mg or placebo. The primary endpoint was demonstration of a significant difference in the rates of remission at week 4 (defined as a Crohn's Disease Activity Index score <150 points) among the 80 mg/40 mg, 160 mg/80 mg, and placebo groups. RESULTS: The rates of remission at week 4

2006 EvidenceUpdates Controlled trial quality: predicted high

148. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Full Text available with Trip Pro

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Bansback N J, Brennan A, Ghatnekar O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of adalimumab (40mg/week), a fully human monoclonal antibody with high affinity and specificity for tumour necrosis factor (TNF), for the treatment of moderate to severe rheumatoid arthritis (RA). Type of intervention Treatment. Economic study type Cost-utility analysis. Study

2005 NHS Economic Evaluation Database.

149. Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review

Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC (...) . Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005 Authors' objectives This study aims to summarise the currently available evidence on adalimumab (Humira) for moderate to severely active Crohn's disease Authors' conclusions Adalimumab (Humira) is a fully human anti-tumour necrosis factor (TNF)-alpha monoclonal antibody in phase III trials for the induction and maintenance of clinical remission

2005 Health Technology Assessment (HTA) Database.

150. Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review

Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Adalimumab (...) (Humira) for moderate to severe psoriatic arthritis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2004 Authors' objectives This study aims to summarise the currently available evidence on adalimumab (Humira) for moderate to severe psoriatic arthritis. Authors' conclusions Adalimumab (Humira) is a fully human anti-TNF-a monoclonal antibody in phase III trials for reducing the signs and symptoms of active psoriatic arthritis (PsA) in adults. It is anticipated

2004 Health Technology Assessment (HTA) Database.

151. Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate

Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate Adalimumab (Humira®) - For the treatment of moderate to severe, active (...) rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis

2003 Health Technology Assessment (HTA) Database.

152. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab (...) when added to methotrexate in patients with active rheumatoid arthritis Hochberg M C, Tracy J K, Hawkins-Holt M, Flores R H CRD summary This review compared adalimumab, etanercept and infliximab when added to methotrexate in patients with active rheumatoid arthritis. The authors concluded that the three agents have similar efficacy when combined with methotrexate. Overall, the methods of analysis may mean that the trials were not powered to detect any true treatment effect differences. Head-to-head

2003 DARE.

153. Adalimumab

Adalimumab Adalimumab Adalimumab Stachnik J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stachnik J. Adalimumab. University HealthSystem Consortium (UHC). Drug Monograph. 2002 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug information

2002 Health Technology Assessment (HTA) Database.